[Below are the Areas of Interest for consideration for GSK’s Assets:]

[For belantamab mafodotin these include (updated December 2025):]
Combination Therapies:
Belamaf in combination with novel treatment options (e.g. CeLMoDs) in late-stage development in Multiple Myeloma where there is no ongoing research
• Induction with T-cell engagers followed by low-dose belamaf maintenance therapy
• Belamaf as bridging therapy prior to T-Cell engagers (e.g. CAR-T).
• Innovative combinations with a strong scientific rationale aimed at addressing areas of high unmet need.

Additional Therapeutic Targets
BCMA expressing malignancies (advanced amyloidosis in Cardiac 3b in both ND and RR ALA).

Pipeline asset(s) proposals may be considered where there is strong rational and data delivery aligns with clinical development of the asset.


[Momelotinib Areas of Interest (updated February 2025):]
Myelofibrosis (MF) Combinations:
Combination of MMB with agents (1L or as 'add-on') with potential for disease modification, not limited to:
• Anti-HJV (e.g., DISC-0974)
• BET inhibitors
• Anti-CALR therapies
• LSD1 inhibitors (e.g. bomedemstat)
• MDM2 inhibitors (e.g., Navtemadlin)
• PIM1 inhibitors (e.g., TP-3654)
• Telomerase inhibitors (e.g., Imetelstat)
• TGFb modulators (e.g., KER-050)
• XPO1 inhibitors (e.g., Selinexor)

Note: Proposals to address other hematologic malignancies may be considered for those with extraordinary scientific rationale (case-by-case)

• Chronic graft-vs-host-disease

[For Dostarlimab these include (updated August 2025):]
Investigation of dostarlimab in Gyn-Onc, Head and Neck, and Colorectal/GI indications that can support current registrational studies through meaningful evidence generation.
Endometrial Cancer
1.   Translational research on anti-PD-(L)1 resistance
2.   ctDNA clinical utility in EC and for IO monitoring
3.   IO combination approaches for IO-exposed EC
4.   IO combination approaches for MMRp/MSS EC
5.   IO for early-stage EC with EBRT sparing strategies

GI
1.   RWD with focus on complementing the AZUR-1 study of dostarlimab in dMMR/MSI-H LARC evaluating dostarlimab as a surgery sparing therapy compared to current SOC
2.   Investigate optimal duration of therapy with dostarlimab (i.e. retreatment, ctDNA guided approach, etc.)

Head and Neck
1.   Investigate novel combinations (e.g. B7H3)
2.   Optimal duration of treatment, IO after IO (retreatment?) sequencing: neoadjuvant, adjuvant, maintenance
3.   Exploration in settings outside of unresected, locally advanced population and beyond HNSCC (nasopharyngeal?)
4.   Exploration in advanced disease with potential for organ-sparing, de-escalation of treatment (including surgery and radiation)

Other
1.   Supporting organ sparing approaches using dostarlimab across other tumors.

[For niraparib, these include (updated November 2024):]
Ovarian Cancer
• Investigation of PARPi monotherapy strategies for identifying the appropriate patient population that could benefit from PARPi monotherapy.
• Optimizing patient experience and mitigation of adverse effects.

Glioblastoma
• Studies exploring treatment strategies in methylated patient population.